JUNE 3, 2025 TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases Read More →
APRIL 8, 2025 TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer Read More →
NOVEMBER 13, 2024 TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development Read More →
JUNE 26, 2024 TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases Read More →
JANUARY 3, 2024 TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration Read More →
